The ATP sensitive potassium channel (K ATP ) is a novel target for migraine drug development

Migraine is one of the leading causes of disability worldwide, affecting work and social life. It has been estimated that sales of migraine medicines will reach 12.9 billion USD in 2027. To reduce social impact, migraine treatments must improve, and the ATP-sensitive potassium (K ) channel is a prom...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in molecular neuroscience 2023-06, Vol.16, p.1182515-1182515
Main Authors: Clement, Amalie, Christensen, Sarah Louise, Jansen-Olesen, Inger, Olesen, Jes, Guo, Song
Format: Article
Language:English
Subjects:
Animal models
Clinical medicine
Clinical trials
Disease prevention
Drug development
drug target
Drugs
Headache
Headaches
KATP antagonist
Kinases
levcromakalim
Migraine
Molecular Neuroscience
Nitric oxide
Peptides
Pharmaceutical industry
Potassium
potassium channel
Potassium channels (inwardly-rectifying)
Proteins
Sales
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Migraine is one of the leading causes of disability worldwide, affecting work and social life. It has been estimated that sales of migraine medicines will reach 12.9 billion USD in 2027. To reduce social impact, migraine treatments must improve, and the ATP-sensitive potassium (K ) channel is a promising target because of the growing evidence of its implications in the pathogenesis of migraine. Strong human data show that opening of the K channel using levcromakalim is the most potent headache and migraine trigger ever tested as it induces headache in almost all healthy subjects and migraine attacks in 100% of migraine sufferers. This review will address the basics of the K channel together with clinical and preclinical data on migraine implications. We argue that K channel blocking, especially the Kir6.1/SUR2B subtype, may be a target for migraine drug development, however translational issues remain. There are no human data on the closure of the K channel, although blocking the channel is effective in animal models of migraine. We believe there is a good likelihood that an antagonist of the Kir6.1/SUR2B subtype of the K channel will be effective in the treatment of migraine. The side effects of such a blocker may be an issue for clinical use, but the risk is likely only moderate. Future clinical trials of a selective Kir6.1/SUR2B blocker will answer these questions.
ISSN:1662-5099
1662-5099
DOI:10.3389/fnmol.2023.1182515